Summit Moving Lead Drugs with Wellcome Trust Award
LONDON – Summit plc is making headway with its two lead programs, winning a £4 million (US$6.42 million) translation award from the Wellcome Trust for clinical trials of SMT19969, a narrow-spectrum antibiotic for treating Clostridium difficile infections.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST